Compositions useful for target, detection, imaging and treatment, and methods of production and use thereof

Patent metadata

Field	Value
Publication number	US-9642926-B2
Application number	US-201113822927-A
Country	US
Kind code	B2
Filing date	Sep 26, 2011
Priority date	Sep 28, 2010
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein.

First claim

What is claimed is:

1. A complex of sequentially deliverable pharmaceutical reagents useful for detecting a target exposed in a lumen through imaging, wherein the complex is formed in vivo, the complex comprising:
a target exposed on a surface of a lumen within a body of a subject;
at least one targeting vesicle bound to the target;
a plurality of amplification vesicles, wherein at least two amplification vesicles are directly bound to a single targeting vesicle;
a plurality of imaging vesicles;
wherein each of the plurality of imaging vesicles is bound to an amplification vesicle, and wherein at least the imaging vesicles are detectable by an imaging modality, thus allowing detection of the complex bound to the target; and
wherein the complex is formed in the lumen within the subject's body and bound to the surface of the lumen, and the target exposed in the lumen is detected via the imaging modality present in the complex.

2. The complex of claim 1 , wherein two or more imaging vesicles are bound to a single amplification vesicle.

3. The complex of claim 1 , wherein the targeting, amplification and imaging vesicles are each selected from the group consisting of liposomes, echogenic liposomes, multimodal echogenic liposomes, microbubbles, microballoons, microspheres, matrix particles, micelles, aggregation based constructs, nanoparticle vesicles, perfluorocarbon nanodroplets, and combinations thereof.

4. The complex of claim 1 , wherein at least one of the targeting, amplification, and imaging vesicles comprises a gas.

5. The complex of claim 1 , wherein at least one the targeting, amplification, and imaging vesicles further comprises a therapeutic composition incorporated/encapsulated therein.

6. The complex of claim 4 , wherein the therapeutic composition is delivered, released, activated and/or excited upon targeting via the targeting vesicle.

7. The complex of claim 5 , wherein the release/activation/excitation is in response to exposure to at least one of heat, ultrasound and chemical methods.

8. The complex of claim 1 , wherein:
(a) the targeting vesicle is further defined as comprising a primary binding site and a plurality of secondary binding sites;
(b) the amplification vesicle is further defined as comprising at least one tertiary binding site and at least one quaternary binding site;
(c) the imaging vesicle is further defined as comprising at least one quinary binding site;
(d) wherein the primary binding site of the targeting vesicle forms a first binding complex with the target, at least two of the secondary binding sites of the targeting vesicle each forms a second binding complex with the tertiary binding site of an amplification vesicle, and the quaternary binding site of an amplification vesicle forms a third binding complex with the quinary binding site of the imaging vesicle.

9. The complex of claim 7 , wherein at least one of:
(a) the tertiary and quaternary binding sites of the amplification vesicle are identical and complementary to each of the plurality of secondary binding sites of the targeting vesicle and the at least one quinary binding site of the imaging vesicle; and
(b) each of the plurality of secondary binding sites of the targeting vesicle is identical to the at least one quaternary binding site of the amplification vesicle, whereby the secondary binding site of the targeting vesicle can also bind the quinary binding site of an imaging vesicle to form the third binding complex.

10. The complex of claim 8 , wherein each of the primary, secondary, tertiary, quaternary and quinary binding sites is selected from the group consisting of peptides, proteins, antigens, antibodies, antibody fragments, receptors, ligands, glycoconjugates, and combinations or derivatives thereof.

11. The complex of claim 1 , wherein the complex further comprises a second imaging vesicle different from the first imaging vesicle, and wherein a first imaging vesicle and a second imaging vesicle are bound to a single amplification vesicle.

12. The complex of claim 11 , wherein the amplification vesicle is provided with two different binding sites to which the first and second imaging vesicles bind.

Assignees

• Oppenheimer Les
• Guracar Ismayil M
• Siemens Medical Solutions Usa Inc

Inventors

• Oppenheimer Les
• Guracar Ismayil M

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K49/227

  Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric · CPC title

• A61K49/0002

  General or multifunctional contrast agents, e.g. chelated agents · CPC title

• A61K41/0052

  Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy · CPC title